Anticipated combination of beta-blocker and angiotensin-converting enzyme inhibitor: new opportunities for optimizing treatment of cardiovascular patients

Yu.M. Sirenko, O.O. Torbas

Abstract


The review presents the information on fixed combination of beta-bblocker bisoprolol and ACE inhibitor perindopril. The clinical situations when this combination usage is most relevant and effective are dwelt.

Keywords


arterial hypertension; fixed combination; bisoprolol; perindopril

References


Бюлетень Національного канцер-реєстру № 16 «Рак в Україні, 2013-2014».

Серцево-судинні захворювання в Україні: прогнози — невтішні // Ваше здоров’я. — 2015. — 09.01.

Державна служба статистики України: Демографічна та соціальна статистика / Охорона здоров’я. Захворюваність населення (за даними Міністерства охорони здоров’я). Режим доступу: http://www.ukrstat.gov.ua/

Asmar R. Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications // Am. J. Cardiovasc. Drugs. — 2001. — Vol. 1(5). — P. 387-97.

Brugts J.J., Ninomiya T., Boersma E. et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials // Eur. Heart J. — 2009. — Vol. 30 (11). — P. 1385-94.

За даними міжнародних підрахунків на основі Ouintiles IMS database, Analytics Link, C7A worldwide, Volume, MAT Q3 2016 DATA Analytics Link.

Campbell D.J. A Review of Perindopril in the Reduction of Cardiovascular Events // J. Vasc. Health Risk Manag. — 2006. — Vol. 2 (2). — P. 117-124.

Cruickshank J.M. Don’t beta blockers still have a role in hypertension? // BMJ. — 2011. —Vol. 343. — d6495.

Dart A.M., Reid C.M., McGrath B.; Tonometry Study Group. Effects of ACE inhibitor therapy on derived central arterial wave forms in hypertension // Am. J. Hypertens. — 2001. — Vol. 14 (8 Pt 1). — P. 804-10.

de Oliveira-Filho A.D., Costa F.A., Neves S.J. et al. Pseudoresistant hypertension due to poor medication adherence // Int. J. Cardiol. — 2014. — Vol. 172 (2). — e309-10.

DiNicolantonio J.J., O’Keefe Vasc J.H. Perindopril for improving cardiovascular events // Health Risk Manag. — 2014. — Vol. 10. — P. 539-548.

Dixon M.S., Thomas P., Sheridan D.J. A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension // Eur. J. Clin. Pharmacol. — 1990. — Vol. 38 (1). — P. 21-4.

Dorow P., Bethge H., Tönnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris // Eur. J. Clin. Pharmacol. — 1986. — Vol. 31 (2). — P. 143-7.

Dudenbostel T., Acelajado M.C., Pisoni R. et al. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure // Hypertension. — 2015. — Vol. 66 (1). — P. 126-133.

Еurostat: statistics-explaine. Режим доступу: http://ec.europa.eu/eurostat/statistics-explained

Fox K.M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. — 2003. — Vol. 362 (9386). — P. 782-8.

Hara M. OACIS: ACE inhibitors led to better survival rates after acute MI // Am. J. Cardiol. — 2014. — Vol. 114. — P. 1-8.

Hsu C.I., Hsiao F.Y., Wu F.L., Shen L.J. Adherence and medication utilisation patterns of fixed-dose and free combination of angiotensin receptor blocker/thiazide diuretics among newly diagnosed hypertensive patients: a population-based cohort study // Int. J. Clin. Pract. — 2015. — Vol. 69 (7). — P. 729-37.

Ishiguro H., Ikeda T., Abe A. et al. Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation // Int. Heart J. — 2008. — Vol. 49 (3). — P. 281-93.

Lauffenburger J.C., Landon J.E., Fischer M.A. Effect of Combination Therapy on Adherence Among US Patients Initiating Therapy for Hypertension: a Cohort Study // Gen. Intern. Med. — 2017 Jan 3.

Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies // BMJ. — 2009. — Vol. 338. — b1665.

Lechat P., Brunhuber K.W., Hofmann R. et al. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial // Lancet. — 1999. — Vol. 35 (9146). — P. 9-13.

Maclean E., Zheng S., Nabeebaccus A. et al. Effect of early bisoprolol administration on ventricular arrhythmia and cardiac death in patients with non-ST elevation myocardial infarction // Heart Asia. — 2015. — Vol. 7 (2). — P. 46-51.

Madej A., Buldak L., Basiak M. et al. The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines // J. Clin. Pharmacol. Ther. — 2009. — Vol. 47(11). — P. 686-94.

Madej A., Bołdys A., Bułdak L. et al. Short-term antihypertensive therapy lowers the C-reactive protein level // Postepy Hig. Med. Dosw. — 2012. — Vol. 66. — P. 78-84.

Mancia G., Kjeldsen S.E., Zappe D.H. et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial // Eur. Heart J. — 2016. — Vol. 37 (12). — P. 955-64.

Mancia G., Rea F., Cuspidi C., Grassi G., Corrao G. Blood pressure control in hypertension. Pros and cons of available treatment strategies // J. Hypertens. — 2017. — Vol. 35 (2). — P. 225-233.

Morgan T.O., Morgan O., Anderson A. Effect of dose on trough peak ratio of antihypertensive drugs in elderly hypertensive males // Clin. Exp. Pharmacol. Physiol. — 1995. — Vol. 22 (10). — P. 778-80.

Ozben B., Sumerkan M., Tanrikulu A.M. et al. Perindopril decreases P wave dispersion in patients with stage 1 hypertension // J. Renin Angiotensin Aldosterone Syst. — 2009. — Vol. 10 (2). — P. 85-90.

Plewan A., Lehmann G., Ndrepepa G. et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol // Eur Heart J. — 2001. — Vol. 22(16). — P. 1504-10.

Proclemer A, Gradnik R, Savonitto S, Feruglio GA. Electrophysiological effects of bisoprolol // Eur. Heart J. — 1987. — Suppl. M. — P. 81-5.

PROGRESS Collaborative Group.Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack // Lancet. — 2001. — Vol. 358 (9287). — P. 1033-41.

Raposeiras-Roubín S., Abu-Assi E., Redondo-Diéguez A. et al. En la era actual existebeneficiopronósticodeltratamiento con bloqueadores beta tras un síndromecoronarioagudo con funciónsistólicaconservada? / Prognostic benefit of beta-blockers after acute coronary syndrome with preserved systolic function. Still rele­vant today? // Esp. Cardiol. — Vol. 68 (7). — P. 585-591.

Sugimoto T., Hayakawa H., Osada H. et al. Clinical evaluation of bisoprolol in the treatment of extrasystoles and sinus tachycardia: an interim report // J. Cardiovasc. Pharmacol. — 1986. — Vol. 8, Suppl. 11. — S171-4.

Taneva B., Davceva’ J., Vavlukis’ M. et al. Bisoprolol reduces episodes of ventricular tachycardia and sudden cardiac death in subjects with chronic heart failure // Eur. J. of Heart Failure. — 2000. — Vol. 2, issue S1. — P. 98-98.

Vrijens B., Vincze G., Kristanto P. et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories // BMJ. — 2008. — Vol. 336 (7653). — P. 1114-1117.

Wang Q., Shang Y., Wang Z. et al. Perindopril for the prevention of atrial fibrillation recurrence after radiofrequency catheter ablation: One-year experience // Heart Rhythm. — 2016. — Vol. 13 (10). — P. 2040-7.

Williams B., O’Rourke M. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT. Anglo-Scandinavian Cardiac Outcomes Trial // J. Hum. Hypertens. — 2001. — Aug; 15 Suppl. 1. — S69-73.

World Health Organization (WHO). The world health report 2003.

Zhang H., Yuan X., Zhang H. et al. Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery // Circulation. — 2015. — Vol. 131 (25). — P. 2194-2201.

Magrini G., Nicolosi G.L., Chiariello M. et al. Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction // Ital. Heart J. — 2005. — Vol. 6. Suppl. 7. — P. 14S-23S.




DOI: https://doi.org/10.22141/2224-1485.4.54.2017.109540

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru